Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Recommendation of “Hold” by Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT) has earned an average recommendation of “Hold” from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $3.1591.

Several equities analysts have recently weighed in on HCAT shares. Stephens reduced their price target on Health Catalyst from $3.50 to $2.00 and set an “equal weight” rating for the company in a research report on Friday. Cantor Fitzgerald cut their target price on Health Catalyst from $4.00 to $3.00 and set a “neutral” rating for the company in a research note on Friday. Citigroup reduced their target price on Health Catalyst from $2.75 to $1.75 and set a “neutral” rating for the company in a report on Friday. Raymond James Financial set a $3.00 price target on Health Catalyst in a research report on Friday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a report on Monday, December 29th.

Health Catalyst Stock Down 26.3%

HCAT opened at $1.32 on Friday. Health Catalyst has a 12 month low of $1.20 and a 12 month high of $5.06. The company has a market cap of $93.36 million, a PE ratio of -0.52 and a beta of 1.76. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.46. The company has a 50 day moving average of $2.05 and a 200 day moving average of $2.56.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Thursday, March 12th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The business had revenue of $74.68 million for the quarter, compared to the consensus estimate of $73.99 million. Health Catalyst had a negative net margin of 57.20% and a negative return on equity of 3.98%. On average, sell-side analysts expect that Health Catalyst will post -0.33 EPS for the current year.

Institutional Trading of Health Catalyst

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Light Asset Management LLC lifted its stake in Health Catalyst by 17.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,230,181 shares of the company’s stock worth $46,108,000 after purchasing an additional 1,793,374 shares in the last quarter. Millennium Management LLC grew its position in shares of Health Catalyst by 2,513.3% during the 3rd quarter. Millennium Management LLC now owns 1,589,536 shares of the company’s stock valued at $4,530,000 after purchasing an additional 1,528,710 shares in the last quarter. RA Capital Management L.P. purchased a new position in shares of Health Catalyst during the 4th quarter valued at $1,897,000. HighMark Wealth Management LLC increased its holdings in shares of Health Catalyst by 139.0% in the fourth quarter. HighMark Wealth Management LLC now owns 741,482 shares of the company’s stock worth $1,772,000 after purchasing an additional 431,200 shares during the period. Finally, Nepsis Inc. increased its holdings in shares of Health Catalyst by 26.6% in the fourth quarter. Nepsis Inc. now owns 1,915,794 shares of the company’s stock worth $4,579,000 after purchasing an additional 402,762 shares during the period. Institutional investors own 85.00% of the company’s stock.

Key Stories Impacting Health Catalyst

Here are the key news stories impacting Health Catalyst this week:

• Positive Sentiment: Revenue and some profitability metrics showed resilience: Q4 revenue slightly beat consensus ($74.68M vs. $73.99M) and the company reported full‑year revenue of $311.1M with Adjusted EBITDA of $41.4M — signals that core demand remains. Health Catalyst Reports Fourth Quarter and Year End 2025 Results
• Positive Sentiment: Some chart/analyst commentary suggests the stock may be finding technical support (hammer pattern) and that earnings‑estimate revisions could stabilize — a possible near‑term bottom for opportunistic buyers. HCAT May Find a Bottom Soon
• Neutral Sentiment: Management has launched a strategic review and the CEO would not rule out a potential sale — this could unlock value but also creates uncertainty around capital allocation and timing. Seeking Alpha: CEO declines to rule out sale
• Negative Sentiment: The quarter showed an EPS miss and continued negative margins — Q4 EPS missed estimates (reported ~$0.08 vs. consensus around $0.10), which undercut confidence in near‑term profitability. MarketBeat Q4 results summary
• Negative Sentiment: Q1 revenue guidance was lowered to $68.0M–$70.0M vs. consensus ~ $74.1M — the guidance shortfall appears to be the main driver of the selloff since it signals softer near‑term top‑line momentum. Earnings press release / guidance
• Negative Sentiment: Multiple sell‑side firms lowered price targets and moved to neutral/hold/equal‑weight (Citigroup to $1.75, Stephens and Stifel to $2.00), increasing downward pressure and reducing buy‑side conviction. Analyst price-target cuts (Benzinga)
• Negative Sentiment: Market reaction was amplified by heavy volume and headlines emphasizing the mixed print and management uncertainty, leading to sharp intraday selling despite the revenue beat. MSN: stock reaction

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.